Lilly not slashing force like its rivals

Share this article:
Eli Lilly CEO Sidney Taurel said the company does not plan any major changes to its sales force, even as rivals cut jobs.

“We won’t grow our sales force,” Taurel said in an interview with the cable network CNBC. “There has been some reduction…of our sales force. But we don’t see major decreases.”

Taurel said Lilly has already decreased its total work force by 4,500, or 10%, since 2004.

Late 2006, Pfizer announced cuts to its US and European sales forces by at least 20%. AstraZeneca said it plans to cut 3,000 jobs, or 4.6% of its workforce. Abbott also announced the phasing out of “several hundred” primary care rep positions.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...